Stan Abel, MBA
Chief Operating Officer & Co-Founder
Stan Abel, who joined ProJenX as President and CEO in April 2022, brings more than 20 years of senior management and financial experience in the life sciences industry. Under his leadership, executive teams with emerging businesses have identified and in-licensed development-stage drug candidates, raised more than $100 million to fund operations, conducted large-scale clinical trials and implemented successful M&A strategies. Prior to joining ProJenX, Abel was CEO of SiteOne Therapeutics Inc., where he led a team developing new treatments for acute and chronic pain. Before this, he was CEO of Corthera Inc. through its sale to Novartis with a focus on a new treatment for heart failure. Earlier in his career, Abel was the CFO of Cerexa Inc. from its inception through its sale to Forest Laboratories. In addition, he was CFO of Peninsula Pharmaceuticals Inc. through its sale to Johnson & Johnson. Abel began his career in finance positions with Eli Lilly and Company and DowBrands Inc.
Abel earned a B.S. in business from Indiana University and an M.B.A., with honors, from the University of Chicago Booth School of Business. He is chairman of SiteOne Therapeutics and serves as an advisor to early-stage life science companies.